30 closest matches · ranked by relevance
Hyperprolactinemia
Primary: To Determine if Adjunct Aripiprazole Will Resolve or Improve Prolactin Related Hormonal Side Effects (Amenorrhea, Oligomenorrhea, Galactorrhea). — 11; 7 Participants
Hyperprolactinemia · Prolactinoma
Primary: Percentage of Subjects That Achieved PRL Normalization as Defined by a Serum Prolactin Level Less Than 25ng/mL at Any Time Point During the Study Treatment Period. — 6…
Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Overall Response Rate (ORR) at 2 Months — 0 Participants
Healthy
Primary: Galactorrhea — 0; 56 percentage of participants
Hyperprolactinemia · Hypogonadism
Primary: Average Change in Number of Luteinizing Hormone (LH) Pulses Over 10 Hours — 3.000 pulses per 10 hour period
Lactation
Primary: Change in Breast Milk Volume Baseline to 7 Days — -12; 429; 44 % change from baseline
Lactation
Primary: Breast Milk Production — 66.1 mL/day
Non-functioning Pituitary Adenomas · Prolactinomas
Primary: Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma — 3.8; 29.35 cmˆ3 — p=<0.05
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120
Lactation Suppressed
Primary: Number of Participants Reporting Breast Pain — 16; 30 Participants
Parkinson's Disease · Hyperprolactinemia
Primary: Number of Participants With Fibrotic Valvular Heart Disease Per 10,000 Participant-Years of Follow-Up — 21; 21; NA; 52 Participants/10,000 Participant-Years
Lactation Suppressed
Primary: Number of Participants Reporting Breast Pain — 10; 32 Participants
Pituitary Adenomas · Prolactinomas
Primary: Change in Tumor Volume — 10 Percent volume
Normal · PCOS
Primary: LH Pulse Frequency — 1.31; 0.91; 1.33; 1.19 pulses/hour
Risperidone-induced Hyperprolactinemia
Primary: Trabecular Bone Mineral Density in the Ultradistal Radius — 192.9; 197.2; 191.0; 194.6 mg/cm^3
Polycystic Ovary Syndrome · Hyperandrogenism
Primary: Change in Progesterone Sensitivity Index Before and After Metformin Treatment. — -4.12; -4.29 % change in LH pulses/day 7 P4 level
Parkinson's Disease · Hyperprolactinemia
Primary: Number of Cabergoline Prescriptions by Database and Indication: Year 1 — 17; 1782; 6; 293 prescriptions
Postmenopause · Aging
Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90
Depression, Bipolar · Depression, Unipolar · Dysthymia
Primary: Dimensional Anhedonia Rating Scale (DARS) Score — 15.75; 33.08 score on a scale
Schizophrenia · Bipolar Disorder · Autistic Disorder
Primary: Height (cm) Z-score at Study Visit — 0.40; 0.09 z-score — p=<0.001
Acromegaly
Primary: IGF-1 Levels — 424 ng/mL — p=< 0.05
Parkinson Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS), Parts 3 (Motor Performance) and 4 (Disability). — 19.2; 17.6; 5.1; 2.9 score on a scale
Obesity
Primary: Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1) — 4.1; 3.6 IU/L
Low Milk Supply
Primary: Increase in Breast Milk Production — 35; 26 Participants
Prolonged QT Interval in EKG and Sudden Death
Primary: Baseline (Pre-Ibutilide) QTcI Intervals — 412; 419 ms — p=0.04
Secondary Amenorrhea
Primary: Secretory Conversion of the Endometrium — 23; 28; 70; 53 participants
Acromegaly
Primary: Percentage of Participants With Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) Observed Response by Dose Class — 20; 28.6; 14.3; 23.1 percentage of…
Acromegaly · Pituitary Gigantism
Primary: Total-group Response Rate at Month 3 — 18.2 Percentage of participants
Diabetic Autonomic Neuropathy
Primary: Change in E/I Ratio From Baseline to Endpoint After 24 Weeks of Intervention With Bromocriptine QR vs Placebo — -0.02; -0.05 E/I ratio change — p=0.603
Breast Cancer
Primary: Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months — -1.5; -1.1 percentage of cells stained positive — p=0.92